Psilocybin: a psychedelic alternative to antidepressants?
Pharmaceutical journal/The pharmaceutical journal – January 01, 2022
Source: OpenAlex
Summary
A single 25mg dose of the hallucinogen psilocybin, combined with psychological support, dramatically improved symptoms for individuals with treatment-resistant depression for up to 12 weeks. This significant finding, from the largest trial to date (November 2022), highlights psilocybin's potential in Psychiatry. Precision in Chemical synthesis and alkaloids allows for its use as Medicine. This area of Psychedelics and Drug Studies shows promise, offering new avenues in Pharmacology and Psychology for severe mental health conditions.
Abstract
In November 2022, the largest trial to date of the psychedelic drug, psilocybin, showed that — alongside psychological support — a single 25mg dose could improve the symptoms of treatment-resistant depression for up to 12 weeks. Previous studies have suggested an antidepressant mechanism for psilocybin therapy and have shown that psilocybin is at least as […]